Amgen (AMGN) Interest Coverage Ratio (2009 - 2026)
Amgen (AMGN) recorded quarterly Interest Coverage Ratio of 4.06 in Q1 2026, down 2.58% quarter-over-quarter from 4.17 in Q4 2025, and up 149.05% on a YoY basis from 1.63 in Q1 2025.
Amgen (AMGN) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Amgen's Interest Coverage Ratio history runs 18 years deep, the most recent figure standing at 4.06 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 149.05% year-over-year to 4.06; the TTM figure through Mar 2026 stood at 3.93 (up 61.22% YoY), while the FY2025 annual figure was 3.3, up 43.27% from the prior year.
- Interest Coverage Ratio was 4.06 for Q1 2026 at Amgen, down from 4.17 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 8.47 in Q1 2022 to a low of 1.2 in Q1 2024.
- Historically, Interest Coverage Ratio has averaged 3.86 across 5 years, with a median of 3.57 in 2023.
- The sharpest annual moves came in 2023 and 2026: Interest Coverage Ratio plunged 71.19% in 2023, then soared 149.05% in 2026.
- A 5-year view of Interest Coverage Ratio shows it stood at 5.37 in 2022, then slumped by 71.19% to 1.55 in 2023, then jumped by 99.84% to 3.09 in 2024, then surged by 34.64% to 4.17 in 2025, then retreated by 2.58% to 4.06 in 2026.
- The last three Interest Coverage Ratio figures came in at 4.06 (Q1 2026), 4.17 (Q4 2025), and 3.69 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -13.73 |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 23.39 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.06 |
| Dec 31, 2025 | 4.17 |
| Sep 30, 2025 | 3.69 |
| Jun 30, 2025 | 3.83 |
| Mar 31, 2025 | 1.63 |
| Dec 31, 2024 | 3.09 |
| Sep 30, 2024 | 2.64 |
| Jun 30, 2024 | 2.36 |
| Mar 31, 2024 | 1.20 |
| Dec 31, 2023 | 1.55 |
| Sep 30, 2023 | 2.66 |
| Jun 30, 2023 | 3.57 |
| Mar 31, 2023 | 3.54 |
| Dec 31, 2022 | 5.37 |
| Sep 30, 2022 | 7.23 |
| Jun 30, 2022 | 6.63 |
| Mar 31, 2022 | 8.47 |
| Dec 31, 2021 | 6.88 |
| Sep 30, 2021 | 8.03 |
| Jun 30, 2021 | 2.95 |